SCHEMBL600317

SCHEMBL600317

CC(C)(C)OC(=O)N1CCCN(C2CCC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.54
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
EPHX1 P07099 1/20 0.48
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PREP P48147 2/20 0.46
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
OGFRL1 Q5TC84 1/20 0.45
RECQL P46063 1/20 0.44
HRH3 Q9Y5N1 2/20 0.44
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507159 0.97 HPGD (0.54) HPGDMEN1KMT2AEPHX1USP2
SCHEMBL6135150 0.95 HPGD (0.56) HPGDMEN1KMT2AEPHX1USP2
SCHEMBL3917887 0.95 HPGD (0.55) HPGDMEN1KMT2AEPHX1USP2
SCHEMBL65017 0.95 HPGD (0.54) HPGDMEN1KMT2AEPHX1USP2
SCHEMBL1971010 0.92 EPHX1 (0.55) HPGDMEN1KMT2AEPHX1USP2
SCHEMBL3859089 0.91 HPGD (0.71) HPGDEPHX1PREPRECQLHRH3
SCHEMBL4383127 0.90 EPHX1 (0.57) HPGDMEN1KMT2AEPHX1USP2
SCHEMBL22595956 0.90 L3MBTL3 (0.50) HPGDMEN1KMT2AEPHX1USP2
SCHEMBL994288 0.89 HPGD (0.58) HPGDEPHX1USP2SMN1; SMN2PREP
SCHEMBL63877 0.89 USP2 (0.53) HPGDEPHX1USP2SMN1; SMN2PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032536-B1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2015-05-06 EP claimed
US-7777031-B2 Substituted pyridyl amide compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2010-08-17 US claimed
EP-2032536-A2 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-11 EP claimed
WO-2007143422-A2 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 WO claimed
US-20070281923-A1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 US claimed
US-9321729-B2 Substituted pyridyl amide compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2016-04-26 US disclosed
EP-2391617-B1 AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC AG (DE) 2015-11-11 EP disclosed
EP-2391617-B1 AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC AG (DE) 2015-11-11 EP disclosed
EP-2032536-B1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2015-05-06 EP disclosed
US-20150087635-A1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2015-03-26 US disclosed
US-8940731-B2 Substituted pyridyl amide compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2015-01-27 US disclosed
US-8912176-B2 Azetidines as histamine H3 receptor antagonists EVOTEC AG (DE) 2014-12-16 US disclosed
WO-2009095394-A1 DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC NEUROSCIENCES GMBH (DE) 2009-08-06 WO disclosed
WO-2009095394-A1 DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC NEUROSCIENCES GMBH (DE) 2009-08-06 WO disclosed
EP-2038269-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-25 EP disclosed
EP-2032536-A2 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-11 EP disclosed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
WO-2008002816-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 WO disclosed
WO-2007143422-A2 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 WO disclosed
US-20070281923-A1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087635-A1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 HPGD 586/4885MEN1 3272/4885KMT2A 215/4885
US-20070281923-A1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 HPGD 586/4885MEN1 3272/4885KMT2A 215/4885
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 HPGD 1351/4885MEN1 2916/4885KMT2A 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.